Dopamine Agonist Drugs Need Compulsion Warning: Group
A Washington, D.C.-based consumer advocacy group has sent a petition to the U.S. Food and Drug Administration saying that dopamine agonist drugs should have a black-box warning about side effects that...To view the full article, register now.
Already a subscriber? Click here to view full article